Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has synthesized cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.

Ubix Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising von Hippel-Lindau disease tumor suppressor ligands coupled to a tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety via linker acting as SHP-2 degradation inducers and reported to be useful for the treatment of cancer.

Massachusetts General Hospital and University of California Oakland have described 15-lipoxygenase (LOX) inhibitors reported to be useful for the treatment of stroke, among others.

The Texas Heart Institute Center for Cardiovascular Care has divulged piperazine-based integrin αLβ2 (LFA-1) and/or integrin α4β1 (ITGA4; VLA-4) agonists reported to be useful for the treatment of diabetes, infertility, pulmonary hypertension, renal failure, myocardial infarction, spinal cord injury, pulmonary fibrosis and Parkinson's diseases.

IFM Due Inc. has identified stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer.

The University of Hong Kong has synthesized silver complexes with high aqueous solubility reported to be useful for the treatment of dental caries.

TYK Medicines Inc. has disclosed transcriptional coactivator YAP1/transcriptional enhancer...

The U.S. Court of Appeals for the Federal Circuit once again delved into genus claims as it affirmed Gilead Sciences Inc.’s win in its inter partes review (IPR) challenge of several claims in a patent held by the University of Minnesota.

Albert-Ludwigs-Universitaet Freiburg has described methyltransferase N6AMT1 (KMT9) inhibitors reported to be useful for the treatment of cancer.

University of Pisa has divulged metformin prodrugs reported to be useful for the treatment of cancer, type 2 diabetes and cardiovascular disorders.